학술논문

Granulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology
Document Type
article
Source
Stem Cell Reports. 18(3)
Subject
Biochemistry and Cell Biology
Biological Sciences
Rare Diseases
Neurosciences
Stem Cell Research - Induced Pluripotent Stem Cell
Frontotemporal Dementia (FTD)
Dementia
Stem Cell Research - Induced Pluripotent Stem Cell - Human
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Brain Disorders
Alzheimer's Disease Related Dementias (ADRD)
Stem Cell Research
ALS
Neurodegenerative
Acquired Cognitive Impairment
Aetiology
2.1 Biological and endogenous factors
Neurological
Good Health and Well Being
Humans
Amyotrophic Lateral Sclerosis
Frontotemporal Dementia
Granulins
Progranulins
Astrocytes
Mutation
DNA-Binding Proteins
Brain
FTD
astrocytes
iPSC
neurodegeneration
neurons
strocyte-neuronal signaling
Clinical Sciences
Biochemistry and cell biology
Language
Abstract
Loss of function (LoF) of TAR-DNA binding protein 43 (TDP-43) and mis-localization, together with TDP-43-positive and hyperphosphorylated inclusions, are found in post-mortem tissue of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients, including those carrying LoF variants in the progranulin gene (GRN). Modeling TDP-43 pathology has been challenging in vivo and in vitro. We present a three-dimensional induced pluripotent stem cell (iPSC)-derived paradigm-mature brain organoids (mbOrg)-composed of cortical-like-astrocytes (iA) and neurons. When devoid of GRN, mbOrgs spontaneously recapitulate TDP-43 mis-localization, hyperphosphorylation, and LoF phenotypes. Mixing and matching genotypes in mbOrgs showed that GRN-/- iA are drivers for TDP-43 pathology. Finally, we rescued TDP-43 LoF by adding exogenous progranulin, demonstrating a link between TDP-43 LoF and progranulin expression. In conclusion, we present an iPSC-derived platform that shows striking features of human TDP-43 proteinopathy and provides a tool for the mechanistic modeling of TDP-43 pathology and patient-tailored therapeutic screening for FTD and ALS.